Purpose

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumors has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.

Conditions

Eligibility

Eligible Ages
All ages
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • There is no age limit for the low risk stratum (stage I ovarian immature teratoma and stage I non-seminoma or seminoma malignant GCT [all sites]) - Standard risk 1: Patient must be < 11 years of age at enrollment - Standard risk 2: Patients must be >= 11 and < 25 years of age at enrollment - Patients enrolling on one of the low risk arms must be newly diagnosed with a stage I germ cell tumor; for the standard risk arms, patients must be newly diagnosed with metastatic germ cell tumor (stage II or higher); histologic confirmation of a primary extracranial germ cell tumor in any of the categories outlined below is required of all patients at enrollment except for those who were initially diagnosed with stage I non-seminoma malignant GCT and later recur during observation post surgery off study; for these patients, if elevated tumor markers rise to > 5 x upper limit of normal (ULN) on at least 2 measurements taken at least 1 week apart, a diagnostic biopsy is not required for enrollment - Low risk stage I immature teratoma (IT); site: ovarian; stage: Children's Oncology Group (COG) stage I, Federation of Gynecology and Obstetrics (FIGO) stage IA and IB; grade: 2 or 3; histology: pure immature teratoma (may contain microscopic foci of yolk sac tumor), mixed immature and mature teratoma, (no pathological evidence of MGCT); tumor markers: alpha-FP =< 1,000 ng/mL, beta-HCG institutional normal; all ages - Low risk stage I non-seminoma MGCT; site: ovarian, testicular, or extragonadal; stage: COG stage I, FIGO stage IA and IB, American Joint Committee on Cancer (AJCC) testicular stage IA, IB and IS; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); all ages - Low risk stage I seminoma-MGCT; site: testicular; stage: COG stage I; AJCC testicular stage IA IB, and IS; histology: must contain at least one of the following: may contain immature/mature teratoma; may NOT contain yolk sac tumor, embryonal carcinoma, or choriocarcinoma; all ages - Standard risk 1 (SR1); site: ovarian, testicular, or extragonadal; stage: COG stage II-IV, FIGO stage IC, FIGO stage II-IV (International Germ Cell Consensus Classification [IGCCC] criteria DO NOT apply); histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age (years) < 11 - Standard risk 2 (SR2) - Site: ovarian; stage: COG stage II and III, FIGO stage IC, II and III; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age (years) >= 11 and < 25 - Site: testicular; stage: COG stage II-IV, AJCC stage II, III, IGCCC good risk; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; tumor markers: must be IGCCC good risk; post op: alpha-FP < 1,000 ng/mL, beta-HCG < 5,000 IU/mL and lactate dehydrogenase (LDH) < 3.0 x normal; age (years) >= 11 and < 25 - Site: extragonadal; stage: COG stage II; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age (years) >= 11 and < 25 - Notes: - IGCCC criteria only apply to SR2 patients with a testicular primary tumor - Use post-op tumor marker levels to determine IGCCC risk group - Stage 1 seminoma patients are not eligible for the standard risk arms of the study - For the low risk stage I non-seminoma MGCT and the standard risk arms, components of yolk sac tumor, embryonal carcinoma, or choriocarcinoma can be mixed with other forms of GCT, such as seminoma or mature or immature teratoma; if yolk sac tumor is the only malignant component present, then it must be deemed by the pathologist to be greater than a "microscopic component" of yolk sac tumor - Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, 2 or 3; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age - Organ function requirements apply ONLY to patients who will receive chemotherapy (SR1 and SR2 patients) - Adequate renal function defined as: - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 (within 7 days prior to enrollment) OR - A serum creatinine based on age/gender as follows (within 7 days prior to enrollment): (mg/dL) - 1 month to < 6 months male: 0.4 female: 0.4 - 6 months to < 1 year male: 0.5 female: 0.5 - 1 to < 2 years male: 0.6 female: 0.6 - 2 to < 6 years male: 0.8 female: 0.8 - 6 to < 10 years male: 1 female: 1 - 10 to < 13 years male: 1.2 female: 1.2 - 13 to < 16 years: male: 1.5 female: 1.4 - >= 16 years male: 1.7 female: 1.4 - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment) - Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 2.5 x upper limit of normal (ULN) for age (for the purpose of this study, the ULN for SGPT is 45 U/L) (within 7 days prior to enrollment) - Peripheral absolute neutrophil count (ANC) >= 1,000/mm^3 (within 7 days prior to enrollment) AND - Platelet count >= 100,000/mm^3 (within 7 days prior to enrollment) - Patients enrolling on the standard risk arms must be medically fit to receive protocol treatment and with no contraindications to protocol treatment - Eligibility criteria to participate in the pilot study of the AYA-Hears instrument (patient reported outcomes [PROs] of ototoxicity) Note: participants in group 1 will not receive AGCT1531 protocol-directed therapy; all other AYA-HEARS patients must be enrolled on the AGCT1531 SR2 arm in order to participate - >= 11 and < 25 years old at enrollment - Able to fluently speak and read English - Has received prior cisplatin- or carboplatin-based chemotherapy regimen for malignancy including diagnoses other than germ cell tumor - Followed for cancer or survivorship care at one of the following institutions: - Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center - Dana Farber/Harvard Cancer Center - Hospital for Sick Children - Children's Hospital of Eastern Ontario - Oregon Health and Science University - Seattle Children's Hospital - Yale University

Exclusion Criteria

  • Patients with any diagnoses not listed including: - Stage I testicular cancer patients who have undergone primary RPLND (retroperitoneal lymph node dissection) - Pure dysgerminoma - Pure mature teratoma - Pure immature teratoma COG stage I, grade I - Pure immature teratoma COG stage I, grade 2,3 with alpha-fetoprotein (AFP) >= 1000 ng/mL - Pure immature teratoma COG stage II - IV or FIGO stage IC to IV - "Poor risk" GCT (age >= 11 years old and COG stage IV ovarian, COG stage III or IV EG, or IGCCC intermediate or poor risk testicular), or - Primary central nervous system (CNS) germ cell tumor - Germ cell tumor with somatic malignant transformation - Spermatocytic seminoma - Patients must have had no prior systemic therapy for the current cancer diagnosis - Patients must have had no prior radiation therapy with the exception of CNS irradiation of brain metastases; (this exception only applies to SR1 patients; any patients over age 11 with distant metastases to brain [stage IV disease] would be considered poor risk and therefore not eligible for this trial) - Patients with significant, pre-existing co-morbid respiratory disease that contraindicate the use of bleomycin are ineligible for the standard risk arms of the trial - Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs; a pregnancy test is required for female patients of childbearing potential; (this criteria applies ONLY to patients who will receive chemotherapy [SR1 and SR2 patients]) - Lactating females who plan to breastfeed their infants; (this criteria applies ONLY to patients who will receive chemotherapy [SR1 and SR2 patients]) - Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation; (this criteria applies ONLY to patients who will receive chemotherapy [SR1 and SR2 patients])

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Arm I (bleomycin, carboplatin, etoposide)
Patients receive bleomycin IV over 10 minutes and carboplatin IV over 1 hour on day 1. Patients also receive etoposide IV over 1-2 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.
  • Procedure: Biopsy
    Undergo a tumor biopsy
    Other names:
    • BIOPSY_TYPE
    • Bx
  • Procedure: Biospecimen Collection
    Undergo blood sample collection
    Other names:
    • Biological Sample Collection
    • Biospecimen Collected
    • Specimen Collection
  • Biological: Bleomycin Sulfate
    Given IV
    Other names:
    • Blanoxan
    • BleMomycine
    • Blenoxane
    • Bleo-cell
    • Bleo-S
    • Bleocin
    • Bleolem
    • Bleomycin Sulfas
    • Bleomycin Sulphate
    • Bleomycini Sulfas
    • Blexane
    • Oil Bleo
  • Drug: Carboplatin
    Given IV
    Other names:
    • Blastocarb
    • Carboplat
    • Carboplatin Hexal
    • Carboplatino
    • Carboplatinum
    • Carbosin
    • Carbosol
    • Carbotec
    • CBDCA
    • Displata
    • Ercar
    • JM-8
    • JM8
    • Nealorin
    • Novoplatinum
    • Paraplatin
    • Paraplatin AQ
    • Paraplatine
    • Platinwas
    • Ribocarbo
  • Procedure: Computed Tomography
    Undergo a CT scan
    Other names:
    • CAT
    • CAT Scan
    • Computed Axial Tomography
    • Computerized Axial Tomography
    • Computerized axial tomography (procedure)
    • Computerized Tomography
    • CT
    • CT Scan
    • tomography
  • Drug: Etoposide
    Given IV
    Other names:
    • Demethyl Epipodophyllotoxin Ethylidine Glucoside
    • EPEG
    • Lastet
    • Toposar
    • Vepesid
    • VP 16
    • VP 16-213
    • VP 16213
    • VP-16
    • VP-16-213
    • VP16
  • Procedure: Magnetic Resonance Imaging
    Undergo MRI
    Other names:
    • Magnetic Resonance
    • Magnetic resonance imaging (procedure)
    • Magnetic Resonance Imaging Scan
    • Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
    • MR
    • MR Imaging
    • MRI
    • MRI Scan
    • NMR Imaging
    • NMRI
    • Nuclear Magnetic Resonance Imaging
  • Other: Pharmacogenomic Study
    Correlative studies
    Other names:
    • PHARMACOGENOMIC
  • Procedure: Pulmonary Function Test
    Undergo a pulmonary function test
    Other names:
    • lung function test
    • PFT
    • Pulmonary Function Testing
    • Pulmonary Function Tests
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other names:
    • Quality of Life Assessment
  • Other: Questionnaire Administration
    Ancillary studies
Experimental
Arm II (bleomycin, etoposide, cisplatin)
Patients receive bleomycin IV over 10 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.
  • Procedure: Biopsy
    Undergo a tumor biopsy
    Other names:
    • BIOPSY_TYPE
    • Bx
  • Procedure: Biospecimen Collection
    Undergo blood sample collection
    Other names:
    • Biological Sample Collection
    • Biospecimen Collected
    • Specimen Collection
  • Biological: Bleomycin Sulfate
    Given IV
    Other names:
    • Blanoxan
    • BleMomycine
    • Blenoxane
    • Bleo-cell
    • Bleo-S
    • Bleocin
    • Bleolem
    • Bleomycin Sulfas
    • Bleomycin Sulphate
    • Bleomycini Sulfas
    • Blexane
    • Oil Bleo
  • Drug: Cisplatin
    Given IV
    Other names:
    • Abiplatin
    • Blastolem
    • Briplatin
    • CDDP
    • Cis-diammine-dichloroplatinum
    • Cis-diamminedichloridoplatinum
    • Cis-diamminedichloro Platinum (II)
    • Cis-diamminedichloroplatinum
    • Cis-dichloroammine Platinum (II)
    • Cis-platinous Diamine Dichloride
    • Cis-platinum
    • Cis-platinum II
    • Cis-platinum II Diamine Dichloride
    • Cismaplat
    • Cisplatina
    • Cisplatinum
    • Cisplatyl
    • Citoplatino
    • Citosin
    • Cysplatyna
    • DDP
    • Lederplatin
    • Metaplatin
    • Neoplatin
    • Peyrone's Chloride
    • Peyrone's Salt
    • Placis
    • Plastistil
    • Platamine
    • Platiblastin
    • Platiblastin-S
    • Platinex
    • Platinol
    • Platinol- AQ
    • Platinol-AQ
    • Platinol-AQ VHA Plus
    • Platinoxan
    • Platinum
    • Platinum Diamminodichloride
    • Platiran
    • Platistin
    • Platosin
  • Procedure: Computed Tomography
    Undergo a CT scan
    Other names:
    • CAT
    • CAT Scan
    • Computed Axial Tomography
    • Computerized Axial Tomography
    • Computerized axial tomography (procedure)
    • Computerized Tomography
    • CT
    • CT Scan
    • tomography
  • Drug: Etoposide
    Given IV
    Other names:
    • Demethyl Epipodophyllotoxin Ethylidine Glucoside
    • EPEG
    • Lastet
    • Toposar
    • Vepesid
    • VP 16
    • VP 16-213
    • VP 16213
    • VP-16
    • VP-16-213
    • VP16
  • Procedure: Magnetic Resonance Imaging
    Undergo MRI
    Other names:
    • Magnetic Resonance
    • Magnetic resonance imaging (procedure)
    • Magnetic Resonance Imaging Scan
    • Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
    • MR
    • MR Imaging
    • MRI
    • MRI Scan
    • NMR Imaging
    • NMRI
    • Nuclear Magnetic Resonance Imaging
  • Other: Pharmacogenomic Study
    Correlative studies
    Other names:
    • PHARMACOGENOMIC
  • Procedure: Pulmonary Function Test
    Undergo a pulmonary function test
    Other names:
    • lung function test
    • PFT
    • Pulmonary Function Testing
    • Pulmonary Function Tests
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other names:
    • Quality of Life Assessment
  • Other: Questionnaire Administration
    Ancillary studies
Experimental
Arm III (bleomycin, etoposide, carboplatin)
Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.
  • Procedure: Biopsy
    Undergo a tumor biopsy
    Other names:
    • BIOPSY_TYPE
    • Bx
  • Procedure: Biospecimen Collection
    Undergo blood sample collection
    Other names:
    • Biological Sample Collection
    • Biospecimen Collected
    • Specimen Collection
  • Biological: Bleomycin Sulfate
    Given IV
    Other names:
    • Blanoxan
    • BleMomycine
    • Blenoxane
    • Bleo-cell
    • Bleo-S
    • Bleocin
    • Bleolem
    • Bleomycin Sulfas
    • Bleomycin Sulphate
    • Bleomycini Sulfas
    • Blexane
    • Oil Bleo
  • Drug: Carboplatin
    Given IV
    Other names:
    • Blastocarb
    • Carboplat
    • Carboplatin Hexal
    • Carboplatino
    • Carboplatinum
    • Carbosin
    • Carbosol
    • Carbotec
    • CBDCA
    • Displata
    • Ercar
    • JM-8
    • JM8
    • Nealorin
    • Novoplatinum
    • Paraplatin
    • Paraplatin AQ
    • Paraplatine
    • Platinwas
    • Ribocarbo
  • Procedure: Computed Tomography
    Undergo a CT scan
    Other names:
    • CAT
    • CAT Scan
    • Computed Axial Tomography
    • Computerized Axial Tomography
    • Computerized axial tomography (procedure)
    • Computerized Tomography
    • CT
    • CT Scan
    • tomography
  • Drug: Etoposide
    Given IV
    Other names:
    • Demethyl Epipodophyllotoxin Ethylidine Glucoside
    • EPEG
    • Lastet
    • Toposar
    • Vepesid
    • VP 16
    • VP 16-213
    • VP 16213
    • VP-16
    • VP-16-213
    • VP16
  • Procedure: Magnetic Resonance Imaging
    Undergo MRI
    Other names:
    • Magnetic Resonance
    • Magnetic resonance imaging (procedure)
    • Magnetic Resonance Imaging Scan
    • Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
    • MR
    • MR Imaging
    • MRI
    • MRI Scan
    • NMR Imaging
    • NMRI
    • Nuclear Magnetic Resonance Imaging
  • Other: Pharmacogenomic Study
    Correlative studies
    Other names:
    • PHARMACOGENOMIC
  • Procedure: Pulmonary Function Test
    Undergo a pulmonary function test
    Other names:
    • lung function test
    • PFT
    • Pulmonary Function Testing
    • Pulmonary Function Tests
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other names:
    • Quality of Life Assessment
  • Other: Questionnaire Administration
    Ancillary studies
Experimental
Arm IV (bleomycin, etoposide, cisplatin)
Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.
  • Procedure: Biopsy
    Undergo a tumor biopsy
    Other names:
    • BIOPSY_TYPE
    • Bx
  • Procedure: Biospecimen Collection
    Undergo blood sample collection
    Other names:
    • Biological Sample Collection
    • Biospecimen Collected
    • Specimen Collection
  • Biological: Bleomycin Sulfate
    Given IV
    Other names:
    • Blanoxan
    • BleMomycine
    • Blenoxane
    • Bleo-cell
    • Bleo-S
    • Bleocin
    • Bleolem
    • Bleomycin Sulfas
    • Bleomycin Sulphate
    • Bleomycini Sulfas
    • Blexane
    • Oil Bleo
  • Drug: Cisplatin
    Given IV
    Other names:
    • Abiplatin
    • Blastolem
    • Briplatin
    • CDDP
    • Cis-diammine-dichloroplatinum
    • Cis-diamminedichloridoplatinum
    • Cis-diamminedichloro Platinum (II)
    • Cis-diamminedichloroplatinum
    • Cis-dichloroammine Platinum (II)
    • Cis-platinous Diamine Dichloride
    • Cis-platinum
    • Cis-platinum II
    • Cis-platinum II Diamine Dichloride
    • Cismaplat
    • Cisplatina
    • Cisplatinum
    • Cisplatyl
    • Citoplatino
    • Citosin
    • Cysplatyna
    • DDP
    • Lederplatin
    • Metaplatin
    • Neoplatin
    • Peyrone's Chloride
    • Peyrone's Salt
    • Placis
    • Plastistil
    • Platamine
    • Platiblastin
    • Platiblastin-S
    • Platinex
    • Platinol
    • Platinol- AQ
    • Platinol-AQ
    • Platinol-AQ VHA Plus
    • Platinoxan
    • Platinum
    • Platinum Diamminodichloride
    • Platiran
    • Platistin
    • Platosin
  • Procedure: Computed Tomography
    Undergo a CT scan
    Other names:
    • CAT
    • CAT Scan
    • Computed Axial Tomography
    • Computerized Axial Tomography
    • Computerized axial tomography (procedure)
    • Computerized Tomography
    • CT
    • CT Scan
    • tomography
  • Drug: Etoposide
    Given IV
    Other names:
    • Demethyl Epipodophyllotoxin Ethylidine Glucoside
    • EPEG
    • Lastet
    • Toposar
    • Vepesid
    • VP 16
    • VP 16-213
    • VP 16213
    • VP-16
    • VP-16-213
    • VP16
  • Procedure: Magnetic Resonance Imaging
    Undergo MRI
    Other names:
    • Magnetic Resonance
    • Magnetic resonance imaging (procedure)
    • Magnetic Resonance Imaging Scan
    • Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
    • MR
    • MR Imaging
    • MRI
    • MRI Scan
    • NMR Imaging
    • NMRI
    • Nuclear Magnetic Resonance Imaging
  • Other: Pharmacogenomic Study
    Correlative studies
    Other names:
    • PHARMACOGENOMIC
  • Procedure: Pulmonary Function Test
    Undergo a pulmonary function test
    Other names:
    • lung function test
    • PFT
    • Pulmonary Function Testing
    • Pulmonary Function Tests
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other names:
    • Quality of Life Assessment
  • Other: Questionnaire Administration
    Ancillary studies
Experimental
Low-Risk (observation)
Patients with low-risk stage I grade 2, 3 ovarian immature teratoma or stage I non-seminoma or seminoma MGCTs undergo observation and can transfer to standard risk arm when eligibility criteria are met. Patients with stage I seminoma testicular MGCT undergo observation, and those with residual/recurrent disease are treated at the discretion of their physician. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial.
  • Other: Best Practice
    Undergo observation
    Other names:
    • standard of care
    • standard therapy
  • Procedure: Biopsy
    Undergo a tumor biopsy
    Other names:
    • BIOPSY_TYPE
    • Bx
  • Procedure: Biospecimen Collection
    Undergo blood sample collection
    Other names:
    • Biological Sample Collection
    • Biospecimen Collected
    • Specimen Collection
  • Procedure: Computed Tomography
    Undergo a CT scan
    Other names:
    • CAT
    • CAT Scan
    • Computed Axial Tomography
    • Computerized Axial Tomography
    • Computerized axial tomography (procedure)
    • Computerized Tomography
    • CT
    • CT Scan
    • tomography
  • Procedure: Magnetic Resonance Imaging
    Undergo MRI
    Other names:
    • Magnetic Resonance
    • Magnetic resonance imaging (procedure)
    • Magnetic Resonance Imaging Scan
    • Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
    • MR
    • MR Imaging
    • MRI
    • MRI Scan
    • NMR Imaging
    • NMRI
    • Nuclear Magnetic Resonance Imaging
  • Other: Pharmacogenomic Study
    Correlative studies
    Other names:
    • PHARMACOGENOMIC
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other names:
    • Quality of Life Assessment
  • Other: Questionnaire Administration
    Ancillary studies

Recruiting Locations

Children's Hospital of Alabama
Birmingham, Alabama 35233
Contact:
Site Public Contact
205-638-9285
oncologyresearch@peds.uab.edu

USA Health Strada Patient Care Center
Mobile, Alabama 36604
Contact:
Site Public Contact
800-388-8721

Anchorage Associates in Radiation Medicine
Anchorage, Alaska 98508
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Anchorage Radiation Therapy Center
Anchorage, Alaska 99504
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Alaska Breast Care and Surgery LLC
Anchorage, Alaska 99508
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Alaska Oncology and Hematology LLC
Anchorage, Alaska 99508
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Alaska Women's Cancer Care
Anchorage, Alaska 99508
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Anchorage Oncology Centre
Anchorage, Alaska 99508
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Katmai Oncology Group
Anchorage, Alaska 99508
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Providence Alaska Medical Center
Anchorage, Alaska 99508
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Kingman Regional Medical Center
Kingman, Arizona 86401
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Banner Children's at Desert
Mesa, Arizona 85202
Contact:
Site Public Contact
480-412-3100

Phoenix Childrens Hospital
Phoenix, Arizona 85016
Contact:
Site Public Contact
602-546-0920

Arkansas Children's Hospital
Little Rock, Arkansas 72202-3591
Contact:
Site Public Contact
501-364-7373

CARTI Cancer Center
Little Rock, Arkansas 72205
Contact:
Site Public Contact
501-906-4199
Research@CARTI.com

Kaiser Permanente-Anaheim
Anaheim, California 92806
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

PCR Oncology
Arroyo Grande, California 93420
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Kaiser Permanente-Bellflower
Bellflower, California 90706
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California 91505
Contact:
Site Public Contact
818-847-4793
Najee.Boucher@providence.org

Kaiser Permanente Downey Medical Center
Downey, California 90242
Contact:
Site Public Contact
626-564-3455

Kaiser Permanente-Fontana
Fontana, California 92335
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

UC San Diego Moores Cancer Center
La Jolla, California 92093
Contact:
Site Public Contact
858-822-5354
cancercto@ucsd.edu

Loma Linda University Medical Center
Loma Linda, California 92354
Contact:
Site Public Contact
909-558-4050

Miller Children's and Women's Hospital Long Beach
Long Beach, California 90806
Contact:
Site Public Contact
562-933-5600

Children's Hospital Los Angeles
Los Angeles, California 90027
Contact:
Site Public Contact
323-361-4110

Kaiser Permanente Los Angeles Medical Center
Los Angeles, California 90027
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Cedars Sinai Medical Center
Los Angeles, California 90048
Contact:
Site Public Contact
310-423-8965

Mattel Children's Hospital UCLA
Los Angeles, California 90095
Contact:
Site Public Contact
310-825-6708

Valley Children's Hospital
Madera, California 93636
Contact:
Site Public Contact
559-353-3000
Research@valleychildrens.org

Providence Queen of The Valley
Napa, California 94558
Contact:
Site Public Contact
707-521-3830

UCSF Benioff Children's Hospital Oakland
Oakland, California 94609
Contact:
Site Public Contact
510-428-3264
cogbchoak@ucsf.edu

Kaiser Permanente-Oakland
Oakland, California 94611
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Children's Hospital of Orange County
Orange, California 92868
Contact:
Site Public Contact
714-509-8646
oncresearch@choc.org

Lucile Packard Children's Hospital Stanford University
Palo Alto, California 94304
Contact:
Site Public Contact
800-694-0012
ccto-office@stanford.edu

University of California Davis Comprehensive Cancer Center
Sacramento, California 95817
Contact:
Site Public Contact
916-734-3089

Kaiser Permanente-San Diego Mission
San Diego, California 92108
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Rady Children's Hospital - San Diego
San Diego, California 92123
Contact:
Site Public Contact
858-966-5934

Naval Medical Center -San Diego
San Diego, California 92134
Contact:
Site Public Contact
619-532-8712

UCSF Medical Center-Mission Bay
San Francisco, California 94158
Contact:
Site Public Contact
877-827-3222
cancertrials@ucsf.edu

Providence Medical Foundation - Santa Rosa
Santa Rosa, California 95403
Contact:
Site Public Contact
707-521-3830

Providence Santa Rosa Memorial Hospital
Santa Rosa, California 95405
Contact:
Site Public Contact
707-521-3830

Children's Hospital Colorado
Aurora, Colorado 80045
Contact:
Site Public Contact
303-764-5056
josh.b.gordon@nsmtp.kp.org

Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado 80218
Contact:
Site Public Contact
303-839-6000

Connecticut Children's Medical Center
Hartford, Connecticut 06106
Contact:
Site Public Contact
860-545-9981

Yale University
New Haven, Connecticut 06520
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Alfred I duPont Hospital for Children
Wilmington, Delaware 19803
Contact:
Site Public Contact
302-651-5572
Allison.bruce@nemours.org

MedStar Georgetown University Hospital
Washington, District of Columbia 20007
Contact:
Site Public Contact
202-444-2223

Children's National Medical Center
Washington, District of Columbia 20010
Contact:
Site Public Contact
202-476-2800
OncCRC_OnCall@childrensnational.org

Broward Health Medical Center
Fort Lauderdale, Florida 33316
Contact:
Site Public Contact
302-651-5572
Allison.bruce@nemours.org

Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida 33908
Contact:
Site Public Contact
239-343-5333
molly.arnstrom@leehealth.org

University of Florida Health Science Center - Gainesville
Gainesville, Florida 32610
Contact:
Site Public Contact
352-273-8010
cancer-center@ufl.edu

Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida 33021
Contact:
Site Public Contact
954-265-1847
OHR@mhs.net

Nemours Children's Clinic-Jacksonville
Jacksonville, Florida 32207
Contact:
Site Public Contact
302-651-5572
Allison.bruce@nemours.org

University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida 33136
Contact:
Site Public Contact
305-243-2647

Nicklaus Children's Hospital
Miami, Florida 33155
Contact:
Site Public Contact
888-624-2778

Miami Cancer Institute
Miami, Florida 33176
Contact:
Site Public Contact
786-596-2000

AdventHealth Orlando
Orlando, Florida 32803
Contact:
Site Public Contact
407-303-2090
FH.Cancer.Research@flhosp.org

Arnold Palmer Hospital for Children
Orlando, Florida 32806
Contact:
Site Public Contact
321-841-5357
Jennifer.spinelli@orlandohealth.com

Nemours Children's Hospital
Orlando, Florida 32827
Contact:
Site Public Contact
302-651-5572
Allison.bruce@nemours.org

Sacred Heart Hospital
Pensacola, Florida 32504
Contact:
Site Public Contact
850-416-4611
eebrou@ascension.org

Johns Hopkins All Children's Hospital
Saint Petersburg, Florida 33701
Contact:
Site Public Contact
727-767-4784
Ashley.Repp@jhmi.edu

Tampa General Hospital
Tampa, Florida 33606
Contact:
Site Public Contact
813-844-7829
syapchanyk@tgh.org

Saint Joseph's Hospital/Children's Hospital-Tampa
Tampa, Florida 33607
Contact:
Site Public Contact
813-357-0849
jennifer.manns@baycare.org

Saint Mary's Hospital
West Palm Beach, Florida 33407
Contact:
Site Public Contact
561-881-2815

Children's Healthcare of Atlanta - Egleston
Atlanta, Georgia 30322
Contact:
Site Public Contact
404-785-2025
Leann.Schilling@choa.org

Augusta University Medical Center
Augusta, Georgia 30912
Contact:
Site Public Contact
706-721-2388
ga_cares@augusta.edu

Medical Center of Central Georgia
Macon, Georgia 31201
Contact:
Site Public Contact
478-633-2152
andrew.weatherall@atriumhealth.org

Memorial Health University Medical Center
Savannah, Georgia 31404
Contact:
Site Public Contact
912-350-7887
Lorraine.OHara@hcahealthcare.com

Straub Clinic and Hospital
Honolulu, Hawaii 96813
Contact:
Site Public Contact
808-522-4333

Kapiolani Medical Center for Women and Children
Honolulu, Hawaii 96826
Contact:
Site Public Contact
808-983-6090

Tripler Army Medical Center
Honolulu, Hawaii 96859
Contact:
Site Public Contact
808-433-6336

Saint Luke's Cancer Institute - Boise
Boise, Idaho 83712
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho 83619
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Saint Luke's Cancer Institute - Meridian
Meridian, Idaho 83642
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Saint Luke's Cancer Institute - Nampa
Nampa, Idaho 83686
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Saint Luke's Cancer Institute - Twin Falls
Twin Falls, Idaho 83301
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Illinois CancerCare-Bloomington
Bloomington, Illinois 61704
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Canton
Canton, Illinois 61520
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Memorial Hospital of Carbondale
Carbondale, Illinois 62902
Contact:
Site Public Contact
618-457-5200
clinical.research@sih.net

SIH Cancer Institute
Carterville, Illinois 62918
Contact:
Site Public Contact
618-985-3333
clinical.research@sih.net

Illinois CancerCare-Carthage
Carthage, Illinois 62321
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Centralia Oncology Clinic
Centralia, Illinois 62801
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Lurie Children's Hospital-Chicago
Chicago, Illinois 60611
Contact:
Site Public Contact
773-880-4562

University of Illinois
Chicago, Illinois 60612
Contact:
Site Public Contact
312-355-3046

University of Chicago Comprehensive Cancer Center
Chicago, Illinois 60637
Contact:
Site Public Contact
773-702-8222
cancerclinicaltrials@bsd.uchicago.edu

Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois 62526
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Decatur Memorial Hospital
Decatur, Illinois 62526
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Illinois CancerCare-Dixon
Dixon, Illinois 61021
Contact:
Site Public Contact
815-285-7800

Crossroads Cancer Center
Effingham, Illinois 62401
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Illinois CancerCare-Eureka
Eureka, Illinois 61530
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois 60201
Contact:
Site Public Contact
847-570-2109

Illinois CancerCare-Galesburg
Galesburg, Illinois 61401
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Western Illinois Cancer Treatment Center
Galesburg, Illinois 61401
Contact:
Site Public Contact
309-344-2831

NorthShore University HealthSystem-Glenbrook Hospital
Glenview, Illinois 60026
Contact:
Site Public Contact
847-570-2109

NorthShore University HealthSystem-Highland Park Hospital
Highland Park, Illinois 60035
Contact:
Site Public Contact
847-570-2109

Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois 61443
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Macomb
Macomb, Illinois 61455
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Cancer Care Center of O'Fallon
O'Fallon, Illinois 62269
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

HSHS Saint Elizabeth's Hospital
O'Fallon, Illinois 62269
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Advocate Children's Hospital-Oak Lawn
Oak Lawn, Illinois 60453
Contact:
Site Public Contact
847-723-7570

Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois 61350
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Advocate Children's Hospital-Park Ridge
Park Ridge, Illinois 60068
Contact:
Site Public Contact
helpdesk@childrensoncologygroup.org

Illinois CancerCare-Pekin
Pekin, Illinois 61554
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
Pekin, Illinois 61554
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Peoria
Peoria, Illinois 61615
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

OSF Saint Francis Radiation Oncology at Peoria Cancer Center
Peoria, Illinois 61615
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Methodist Medical Center of Illinois
Peoria, Illinois 61636
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

OSF Saint Francis Medical Center
Peoria, Illinois 61637
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Saint Jude Midwest Affiliate
Peoria, Illinois 61637
Contact:
Site Public Contact
888-226-4343

Illinois CancerCare-Peru
Peru, Illinois 61354
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Valley Radiation Oncology
Peru, Illinois 61354
Contact:
Site Public Contact
815-664-4141

Illinois CancerCare-Princeton
Princeton, Illinois 61356
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Saint John's Hospital
Springfield, Illinois 62702
Contact:
Site Public Contact
217-525-5666
diana.weyhenmeyer@st-johns.org

Southern Illinois University School of Medicine
Springfield, Illinois 62702
Contact:
Site Public Contact
217-545-7929

Springfield Clinic
Springfield, Illinois 62702
Contact:
Site Public Contact
800-444-7541

Illinois CancerCare - Washington
Washington, Illinois 61571
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Riley Hospital for Children
Indianapolis, Indiana 46202
Contact:
Site Public Contact
800-248-1199

Ascension Saint Vincent Indianapolis Hospital
Indianapolis, Indiana 46260
Contact:
Site Public Contact
317-338-2194
research@stvincent.org

Mission Cancer and Blood - Ankeny
Ankeny, Iowa 50023
Contact:
Site Public Contact
515-282-2921

Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa 50325
Contact:
Site Public Contact
515-241-3305

Mercy Cancer Center-West Lakes
Clive, Iowa 50325
Contact:
Site Public Contact
515-358-6613
cancerresearch@mercydesmoines.org

Greater Regional Medical Center
Creston, Iowa 50801
Contact:
Site Public Contact
515-358-6613
cancerresearch@mercydesmoines.org

Blank Children's Hospital
Des Moines, Iowa 50309
Contact:
Site Public Contact
515-241-8912
samantha.mallory@unitypoint.org

Mercy Medical Center - Des Moines
Des Moines, Iowa 50314
Contact:
Site Public Contact
515-358-6613
cancerresearch@mercydesmoines.org

Mission Cancer and Blood - Laurel
Des Moines, Iowa 50314
Contact:
Site Public Contact
515-241-3305

University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa 52242
Contact:
Site Public Contact
800-237-1225

Mercy Medical Center-West Lakes
West Des Moines, Iowa 50266
Contact:
Site Public Contact
515-358-6613
cancerresearch@mercydesmoines.org

University of Kentucky/Markey Cancer Center
Lexington, Kentucky 40536
Contact:
Site Public Contact
859-257-3379

Norton Children's Hospital
Louisville, Kentucky 40202
Contact:
Site Public Contact
502-629-5500
CancerResource@nortonhealthcare.org

Children's Hospital New Orleans
New Orleans, Louisiana 70118
Contact:
Site Public Contact
CHResearch@lcmchealth.org

Ochsner Medical Center Jefferson
New Orleans, Louisiana 70121
Contact:
Site Public Contact
504-842-8084
Elisemarie.curry@ochsner.org

Eastern Maine Medical Center
Bangor, Maine 04401
Contact:
Site Public Contact
207-973-4274

Maine Medical Center-Bramhall Campus
Portland, Maine 04102
Contact:
Site Public Contact
207-885-7565

Maine Children's Cancer Program
Scarborough, Maine 04074
Contact:
Site Public Contact
207-396-7581
sverwys@mmc.org

Maine Medical Center- Scarborough Campus
Scarborough, Maine 04074
Contact:
Site Public Contact
207-396-8090
wrighd@mmc.org

University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland 21201
Contact:
Site Public Contact
800-888-8823

Sinai Hospital of Baltimore
Baltimore, Maryland 21215
Contact:
Site Public Contact
410-601-6120
pridgely@lifebridgehealth.org

Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland 21287
Contact:
Site Public Contact
410-955-8804
jhcccro@jhmi.edu

Walter Reed National Military Medical Center
Bethesda, Maryland 20889-5600
Contact:
Site Public Contact
301-319-2100

Tufts Medical Center
Boston, Massachusetts 02111
Contact:
Site Public Contact
617-636-5000
ContactUsCancerCenter@TuftsMedicalCenter.org

Massachusetts General Hospital Cancer Center
Boston, Massachusetts 02114
Contact:
Site Public Contact
877-726-5130

Dana-Farber Cancer Institute
Boston, Massachusetts 02215
Contact:
Site Public Contact
877-442-3324

Baystate Medical Center
Springfield, Massachusetts 01199
Contact:
Site Public Contact
413-794-3565
tamara.wrenn@baystatehealth.org

UMass Memorial Medical Center - University Campus
Worcester, Massachusetts 01655
Contact:
Site Public Contact
508-856-3216
cancer.research@umassmed.edu

C S Mott Children's Hospital
Ann Arbor, Michigan 48109
Contact:
Site Public Contact
800-865-1125

Bronson Battle Creek
Battle Creek, Michigan 49017
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Children's Hospital of Michigan
Detroit, Michigan 48201
Contact:
Site Public Contact
helpdesk@childrensoncologygroup.org

Michigan State University Clinical Center
East Lansing, Michigan 48824
Contact:
Site Public Contact
517-975-9547

Helen DeVos Children's Hospital at Spectrum Health
Grand Rapids, Michigan 49503
Contact:
Site Public Contact
616-267-1925
crcwm-regulatory@crcwm.org

Spectrum Health at Butterworth Campus
Grand Rapids, Michigan 49503
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Trinity Health Grand Rapids Hospital
Grand Rapids, Michigan 49503
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Bronson Methodist Hospital
Kalamazoo, Michigan 49007
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

West Michigan Cancer Center
Kalamazoo, Michigan 49007
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Borgess Medical Center
Kalamazoo, Michigan 49048
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Trinity Health Muskegon Hospital
Muskegon, Michigan 49444
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Corewell Health Lakeland Hospitals - Niles Hospital
Niles, Michigan 49120
Contact:
Site Public Contact
616-391-1230

Corewell Health Reed City Hospital
Reed City, Michigan 49677
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Beaumont Children's Hospital-Royal Oak
Royal Oak, Michigan 48073
Contact:
Site Public Contact
248-551-7695

Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
Saint Joseph, Michigan 49085
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Lakeland Medical Center Saint Joseph
Saint Joseph, Michigan 49085
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Munson Medical Center
Traverse City, Michigan 49684
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

University of Michigan Health - West
Wyoming, Michigan 49519
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Children's Hospitals and Clinics of Minnesota - Minneapolis
Minneapolis, Minnesota 55404
Contact:
Site Public Contact
612-813-5913
pauline.mitby@childrensmn.org

University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota 55455
Contact:
Site Public Contact
612-624-2620

Mayo Clinic in Rochester
Rochester, Minnesota 55905
Contact:
Site Public Contact
855-776-0015

University of Mississippi Medical Center
Jackson, Mississippi 39216
Contact:
Site Public Contact
601-815-6700

Saint Francis Medical Center
Cape Girardeau, Missouri 63703
Contact:
Site Public Contact
573-334-2230
sfmc@sfmc.net

Southeast Cancer Center
Cape Girardeau, Missouri 63703
Contact:
Site Public Contact
573-651-5550

Parkland Health Center - Farmington
Farmington, Missouri 63640
Contact:
Site Public Contact
314-996-5569

Capital Region Southwest Campus
Jefferson City, Missouri 65109
Contact:
Site Public Contact
573-632-4851
amy.franken@health.missouri.edu

Children's Mercy Hospitals and Clinics
Kansas City, Missouri 64108
Contact:
Site Public Contact
816-302-6808
rryan@cmh.edu

Lake Regional Hospital
Osage Beach, Missouri 65065
Contact:
Site Public Contact
573-302-2768
clinicaltrials@lakeregional.com

Washington University School of Medicine
Saint Louis, Missouri 63110
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Missouri Baptist Medical Center
Saint Louis, Missouri 63131
Contact:
Site Public Contact
314-996-5569

Mercy Hospital Saint Louis
Saint Louis, Missouri 63141
Contact:
Site Public Contact
314-251-7066

Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri 63670
Contact:
Site Public Contact
314-996-5569

Missouri Baptist Sullivan Hospital
Sullivan, Missouri 63080
Contact:
Site Public Contact
314-996-5569

BJC Outpatient Center at Sunset Hills
Sunset Hills, Missouri 63127
Contact:
Site Public Contact
314-996-5569

Saint Patrick Hospital - Community Hospital
Missoula, Montana 59802
Contact:
Site Public Contact
406-327-3118
amy.hanneman@providence.org

Children's Hospital and Medical Center of Omaha
Omaha, Nebraska 68114
Contact:
Site Public Contact
402-955-3949

University of Nebraska Medical Center
Omaha, Nebraska 68198
Contact:
Site Public Contact
402-559-6941
unmcrsa@unmc.edu

Carson Tahoe Regional Medical Center
Carson City, Nevada 89703
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Comprehensive Cancer Centers of Nevada - Henderson
Henderson, Nevada 89052
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Comprehensive Cancer Centers of Nevada-Horizon Ridge
Henderson, Nevada 89052
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

OptumCare Cancer Care at Seven Hills
Henderson, Nevada 89052
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Comprehensive Cancer Centers of Nevada-Southeast Henderson
Henderson, Nevada 89074
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Las Vegas Urology - Green Valley
Henderson, Nevada 89074
Contact:
Site Public Contact
research@sncrf.org

Las Vegas Urology - Pebble
Henderson, Nevada 89074
Contact:
Site Public Contact
research@sncrf.org

Urology Specialists of Nevada - Green Valley
Henderson, Nevada 89074
Contact:
Site Public Contact
research@sncrf.org

Las Vegas Urology - Pecos
Las Vegas, Nevada 89074
Contact:
Site Public Contact
research@sncrf.org

OptumCare Cancer Care at Charleston
Las Vegas, Nevada 89102
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

University Medical Center of Southern Nevada
Las Vegas, Nevada 89102
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Hope Cancer Care of Nevada
Las Vegas, Nevada 89103
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Radiation Oncology Centers of Nevada Central
Las Vegas, Nevada 89106
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Urology Specialists of Nevada - Central
Las Vegas, Nevada 89106
Contact:
Site Public Contact
research@sncrf.org

Women's Cancer Center of Nevada
Las Vegas, Nevada 89106
Contact:
Site Public Contact
702-693-6870
jamador@wccenter.com

Sunrise Hospital and Medical Center
Las Vegas, Nevada 89109
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Las Vegas Urology - Sunset
Las Vegas, Nevada 89113
Contact:
Site Public Contact
research@sncrf.org

Urology Specialists of Nevada - Southwest
Las Vegas, Nevada 89113
Contact:
Site Public Contact
research@sncrf.org

Radiation Oncology Centers of Nevada Southeast
Las Vegas, Nevada 89119
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Ann M Wierman MD LTD
Las Vegas, Nevada 89128
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Comprehensive Cancer Centers of Nevada - Northwest
Las Vegas, Nevada 89128
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Las Vegas Urology - Cathedral Rock
Las Vegas, Nevada 89128
Contact:
Site Public Contact
research@sncrf.org

Las Vegas Urology - Smoke Ranch
Las Vegas, Nevada 89128
Contact:
Site Public Contact
research@smcrf.org

OptumCare Cancer Care at MountainView
Las Vegas, Nevada 89128
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Urology Specialists of Nevada - Northwest
Las Vegas, Nevada 89128
Contact:
Site Public Contact
research@sncrf.org

Alliance for Childhood Diseases/Cure 4 the Kids Foundation
Las Vegas, Nevada 89135
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Comprehensive Cancer Centers of Nevada - Town Center
Las Vegas, Nevada 89144
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Comprehensive Cancer Centers of Nevada-Summerlin
Las Vegas, Nevada 89144
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Summerlin Hospital Medical Center
Las Vegas, Nevada 89144
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada 89148
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada 89148
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada 89169
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Hope Cancer Care of Nevada-Pahrump
Pahrump, Nevada 89048
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Renown Regional Medical Center
Reno, Nevada 89502
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Saint Mary's Regional Medical Center
Reno, Nevada 89503
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Radiation Oncology Associates
Reno, Nevada 89509
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, New Hampshire 03756
Contact:
Site Public Contact
800-639-6918
cancer.research.nurse@dartmouth.edu

Hackensack University Medical Center
Hackensack, New Jersey 07601
Contact:
Site Public Contact
201-996-2879

Morristown Medical Center
Morristown, New Jersey 07960
Contact:
Site Public Contact
973-971-5900

Saint Peter's University Hospital
New Brunswick, New Jersey 08901
Contact:
Site Public Contact
732-745-8600
kcovert@saintpetersuh.com

Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
New Brunswick, New Jersey 08903
Contact:
Site Public Contact
732-235-8675

Newark Beth Israel Medical Center
Newark, New Jersey 07112
Contact:
Site Public Contact
973-926-7230
Christine.Kosmides@rwjbh.org

Saint Joseph's Regional Medical Center
Paterson, New Jersey 07503
Contact:
Site Public Contact
973-754-2207
HallL@sjhmc.org

University of New Mexico Cancer Center
Albuquerque, New Mexico 87102
Contact:
Site Public Contact
505-925-0348
HSC-ClinicalTrialInfo@salud.unm.edu

Albany Medical Center
Albany, New York 12208
Contact:
Site Public Contact
518-262-5513

Montefiore Medical Center-Einstein Campus
Bronx, New York 10461
Contact:
Site Public Contact
718-379-6866
eskwak@montefiore.org

Montefiore Medical Center-Weiler Hospital
Bronx, New York 10461
Contact:
Site Public Contact
718-379-6866
eskwak@montefiore.org

Children's Hospital at Montefiore
Bronx, New York 10467
Contact:
Site Public Contact
718-379-6866
aaraiza@montefiore.org

Montefiore Medical Center - Moses Campus
Bronx, New York 10467
Contact:
Site Public Contact
718-379-6866
eskwak@montefiore.org

Maimonides Medical Center
Brooklyn, New York 11219
Contact:
Site Public Contact
718-765-2500

Roswell Park Cancer Institute
Buffalo, New York 14263
Contact:
Site Public Contact
800-767-9355
askroswell@roswellpark.org

NYU Winthrop Hospital
Mineola, New York 11501
Contact:
Site Public Contact
212-263-4432
cancertrials@nyulangone.org

The Steven and Alexandra Cohen Children's Medical Center of New York
New Hyde Park, New York 11040
Contact:
Site Public Contact
718-470-3460

Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York 10016
Contact:
Site Public Contact
CancerTrials@nyulangone.org

Mount Sinai Hospital
New York, New York 10029
Contact:
Site Public Contact
212-824-7309
CCTO@mssm.edu

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York 10032
Contact:
Site Public Contact
212-305-6361
nr2616@cumc.columbia.edu

Memorial Sloan Kettering Cancer Center
New York, New York 10065
Contact:
Site Public Contact
212-639-7592

University of Rochester
Rochester, New York 14642
Contact:
Site Public Contact
585-275-5830

Stony Brook University Medical Center
Stony Brook, New York 11794
Contact:
Site Public Contact
800-862-2215

State University of New York Upstate Medical University
Syracuse, New York 13210
Contact:
Site Public Contact
315-464-5476

New York Medical College
Valhalla, New York 10595
Contact:
Site Public Contact
914-594-3794

Westchester Medical Center
Valhalla, New York 10595
Contact:
Site Public Contact
888-823-5923
ctsucontact@westat.com

Mission Hospital
Asheville, North Carolina 28801
Contact:
Site Public Contact
828-213-7055
NCDV.ResearchRegulatory@HCAHealthcare.com

UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina 27599
Contact:
Site Public Contact
877-668-0683
cancerclinicaltrials@med.unc.edu

Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina 28203
Contact:
Site Public Contact
800-804-9376

Novant Health Presbyterian Medical Center
Charlotte, North Carolina 28204
Contact:
Site Public Contact
980-201-6360
kashah@novanthealth.org

Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina 28328
Contact:
Site Public Contact
919-587-9084
jfields@cancersmoc.com

Duke University Medical Center
Durham, North Carolina 27710
Contact:
Site Public Contact
888-275-3853

Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina 27534
Contact:
Site Public Contact
919-587-9084
jfields@cancersmoc.com

East Carolina University
Greenville, North Carolina 27834
Contact:
Site Public Contact
252-744-1015
eubankss@ecu.edu

Southeastern Medical Oncology Center-Jacksonville
Jacksonville, North Carolina 28546
Contact:
Site Public Contact
910-587-9084
jfields@cancersmoc.com

Wake Forest University Health Sciences
Winston-Salem, North Carolina 27157
Contact:
Site Public Contact
336-713-6771

Sanford Broadway Medical Center
Fargo, North Dakota 58122
Contact:
Site Public Contact
701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org

Children's Hospital Medical Center of Akron
Akron, Ohio 44308
Contact:
Site Public Contact
330-543-3193

Strecker Cancer Center-Belpre
Belpre, Ohio 45714
Contact:
Site Public Contact
800-523-3977
sheree@columbusccop.org

Adena Regional Medical Center
Chillicothe, Ohio 45601
Contact:
Site Public Contact
877-779-7585
sheree@columbusccop.org

Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio 45229
Contact:
Site Public Contact
513-636-2799
cancer@cchmc.org

Case Western Reserve University
Cleveland, Ohio 44106
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

Rainbow Babies and Childrens Hospital
Cleveland, Ohio 44106
Contact:
Site Public Contact
216-844-5437

Cleveland Clinic Foundation
Cleveland, Ohio 44195
Contact:
Site Public Contact
866-223-8100
TaussigResearch@ccf.org

Nationwide Children's Hospital
Columbus, Ohio 43205
Contact:
Site Public Contact
614-722-6039
Melinda.Triplet@nationwidechildrens.org

Mount Carmel East Hospital
Columbus, Ohio 43213
Contact:
Site Public Contact
614-488-2118
sheree@columbusccop.org

Columbus Oncology and Hematology Associates Inc
Columbus, Ohio 43214
Contact:
Site Public Contact
614-488-2118
sheree@columbusccop.org

Riverside Methodist Hospital
Columbus, Ohio 43214
Contact:
Site Public Contact
614-566-4475
sheree@columbusccop.org

Grant Medical Center
Columbus, Ohio 43215
Contact:
Site Public Contact
614-566-4475
sheree@columbusccop.org

The Mark H Zangmeister Center
Columbus, Ohio 43219
Contact:
Site Public Contact
614-488-2118
sheree@columbusccop.org

Mount Carmel Health Center West
Columbus, Ohio 43222
Contact:
Site Public Contact
614-234-5433
sheree@columbusccop.org

Doctors Hospital
Columbus, Ohio 43228
Contact:
Site Public Contact
614-566-3275
sheree@columbusccop.org

Dayton Children's Hospital
Dayton, Ohio 45404
Contact:
Site Public Contact
800-228-4055

Delaware Health Center-Grady Cancer Center
Delaware, Ohio 43015
Contact:
Site Public Contact
740-615-0227
sheree@columbusccop.org

Grady Memorial Hospital
Delaware, Ohio 43015
Contact:
Site Public Contact
740-615-2403
sheree@columbusccop.org

Columbus Oncology and Hematology Associates
Dublin, Ohio 43016
Contact:
Site Public Contact
614-566-3275
sheree@columbusccop.org

Dublin Methodist Hospital
Dublin, Ohio 43016
Contact:
Site Public Contact
800-752-9119
sheree@columbusccop.org

Mount Carmel Grove City Hospital
Grove City, Ohio 43123
Contact:
Site Public Contact
877-779-7585
sheree@columbusccop.org

Saint Rita's Medical Center
Lima, Ohio 45801
Contact:
Site Public Contact
419-226-9617

OhioHealth Mansfield Hospital
Mansfield, Ohio 44903
Contact:
Site Public Contact
419-526-8018
sheree@columbusccop.org

Marietta Memorial Hospital
Marietta, Ohio 45750
Contact:
Site Public Contact
800-523-3977
sheree@columbusccop.org

OhioHealth Marion General Hospital
Marion, Ohio 43302
Contact:
Site Public Contact
614-488-2118
sheree@columbusccop.org

Memorial Hospital
Marysville, Ohio 43040
Contact:
Site Public Contact
614-488-2118
sheree@columbusccop.org

Knox Community Hospital
Mount Vernon, Ohio 43050
Contact:
Site Public Contact
740-393-9000
sheree@columbusccop.org

Licking Memorial Hospital
Newark, Ohio 43055
Contact:
Site Public Contact
740-348-4000
sheree@columbusccop.org

Mercy Health Perrysburg Cancer Center
Perrysburg, Ohio 43551
Contact:
Site Public Contact
614-488-2118
sheree@columbusccop.org

Southern Ohio Medical Center
Portsmouth, Ohio 45662
Contact:
Site Public Contact
614-488-2118
sheree@columbusccop.org

ProMedica Flower Hospital
Sylvania, Ohio 43560
Contact:
Site Public Contact
419-824-1842
PCIOncResearch@promedica.org

ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
Toledo, Ohio 43606
Contact:
Site Public Contact
419-824-1842
PCIOncResearch@promedica.org

Saint Vincent Mercy Medical Center
Toledo, Ohio 43608
Contact:
Site Public Contact
614-488-2118
sheree@columbusccop.org

Mercy Health - Saint Anne Hospital
Toledo, Ohio 43623
Contact:
Site Public Contact
614-488-2118
sheree@columbusccop.org

Saint Ann's Hospital
Westerville, Ohio 43081
Contact:
Site Public Contact
614-234-5433
sheree@columbusccop.org

Clinton Memorial Hospital
Wilmington, Ohio 45177
Contact:
Site Public Contact
937-283-2273

Genesis Healthcare System Cancer Care Center
Zanesville, Ohio 43701
Contact:
Site Public Contact
740-454-5232
sheree@columbusccop.org

University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma 73104
Contact:
Site Public Contact
405-271-8777
ou-clinical-trials@ouhsc.edu

Saint Charles Health System
Bend, Oregon 97701
Contact:
Site Public Contact
541-706-2909
nosall@stcharleshealthcare.org

Clackamas Radiation Oncology Center
Clackamas, Oregon 97015
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Providence Cancer Institute Clackamas Clinic
Clackamas, Oregon 97015
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Bay Area Hospital
Coos Bay, Oregon 97420
Contact:
Site Public Contact
541-269-8392
cherie.cox@bayareahospital.org

Providence Newberg Medical Center
Newberg, Oregon 97132
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Providence Willamette Falls Medical Center
Oregon City, Oregon 97045
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Providence Portland Medical Center
Portland, Oregon 97213
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Providence Saint Vincent Medical Center
Portland, Oregon 97225
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Legacy Emanuel Children's Hospital
Portland, Oregon 97227
Contact:
Site Public Contact
503-413-2560

Oregon Health and Science University
Portland, Oregon 97239
Contact:
Site Public Contact
503-494-1080
trials@ohsu.edu

Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania 18103
Contact:
Site Public Contact
610-402-9543
Morgan_M.Horton@lvhn.org

Geisinger Medical Center
Danville, Pennsylvania 17822
Contact:
Site Public Contact
570-271-5251
HemonCCTrials@geisinger.edu

Penn State Children's Hospital
Hershey, Pennsylvania 17033
Contact:
Site Public Contact
717-531-6012

Children's Hospital of Philadelphia
Philadelphia, Pennsylvania 19104
Contact:
Site Public Contact
267-425-5544
CancerTrials@email.chop.edu

University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania 19104
Contact:
Site Public Contact
800-474-9892

Saint Christopher's Hospital for Children
Philadelphia, Pennsylvania 19134
Contact:
Site Public Contact
215-427-8991

UPMC-Magee Womens Hospital
Pittsburgh, Pennsylvania 15213
Contact:
Site Public Contact
412-647-2811

Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania 15224
Contact:
Site Public Contact
412-692-8570
jean.tersak@chp.edu

University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania 15232
Contact:
Site Public Contact
412-647-8073

UPMC-Passavant Hospital
Pittsburgh, Pennsylvania 15237
Contact:
Site Public Contact
412-367-6454

Rhode Island Hospital
Providence, Rhode Island 02903
Contact:
Site Public Contact
401-444-1488

Prisma Health Cancer Institute - Spartanburg
Boiling Springs, South Carolina 29316
Contact:
Site Public Contact
864-241-6251

Medical University of South Carolina
Charleston, South Carolina 29425
Contact:
Site Public Contact
843-792-9321
hcc-clinical-trials@musc.edu

Prisma Health Richland Hospital
Columbia, South Carolina 29203
Contact:
Site Public Contact
864-241-6251

Gibbs Cancer Center-Gaffney
Gaffney, South Carolina 29341
Contact:
Site Public Contact
864-560-6104
kmertz-rivera@gibbscc.org

Saint Francis Hospital
Greenville, South Carolina 29601
Contact:
Site Public Contact
864-603-6213
melissa_beckman@bshsi.org

BI-LO Charities Children's Cancer Center
Greenville, South Carolina 29605
Contact:
Site Public Contact
864-241-6251

Prisma Health Cancer Institute - Butternut
Greenville, South Carolina 29605
Contact:
Site Public Contact
864-241-6251

Prisma Health Cancer Institute - Faris
Greenville, South Carolina 29605
Contact:
Site Public Contact
864-241-6251

Prisma Health Greenville Memorial Hospital
Greenville, South Carolina 29605
Contact:
Site Public Contact
864-241-6251

Saint Francis Cancer Center
Greenville, South Carolina 29607
Contact:
Site Public Contact
864-603-6213
melissa_beckman@bshsi.org

Prisma Health Cancer Institute - Eastside
Greenville, South Carolina 29615
Contact:
Site Public Contact
864-241-6251

Prisma Health Cancer Institute - Greer
Greer, South Carolina 29650
Contact:
Site Public Contact
864-241-6251

Gibbs Cancer Center-Pelham
Greer, South Carolina 29651
Contact:
Site Public Contact
864-560-6104
kmertz-rivera@gibbscc.org

Prisma Health Cancer Institute - Seneca
Seneca, South Carolina 29672
Contact:
Site Public Contact
864-241-6251

North Grove Medical Park
Spartanburg, South Carolina 29303
Contact:
Site Public Contact
864-560-6812

Spartanburg Medical Center
Spartanburg, South Carolina 29303
Contact:
Site Public Contact
864-560-6104
kmertz-rivera@gibbscc.org

Spartanburg Medical Center - Mary Black Campus
Spartanburg, South Carolina 29307
Contact:
Site Public Contact
864-560-6812

MGC Hematology Oncology-Union
Union, South Carolina 29379
Contact:
Site Public Contact
864-560-6104
kmertz-rivera@gibbscc.org

Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota 57117-5134
Contact:
Site Public Contact
605-312-3320
OncologyClinicalTrialsSF@SanfordHealth.org

T C Thompson Children's Hospital
Chattanooga, Tennessee 37403
Contact:
Site Public Contact
423-778-7289

East Tennessee Childrens Hospital
Knoxville, Tennessee 37916
Contact:
Site Public Contact
865-541-8266

Saint Jude Children's Research Hospital
Memphis, Tennessee 38105
Contact:
Site Public Contact
888-226-4343
referralinfo@stjude.org

The Children's Hospital at TriStar Centennial
Nashville, Tennessee 37203
Contact:
Site Public Contact
615-342-1919

Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee 37232
Contact:
Site Public Contact
800-811-8480

Texas Tech University Health Sciences Center-Amarillo
Amarillo, Texas 79106
Contact:
Site Public Contact
806-354-5411

Dell Children's Medical Center of Central Texas
Austin, Texas 78723
Contact:
Site Public Contact
512-628-1902
TXAUS-DL-SFCHemonc.research@ascension.org

Driscoll Children's Hospital
Corpus Christi, Texas 78411
Contact:
Site Public Contact
361-694-5311
Crystal.DeLosSantos@dchstx.org

Medical City Dallas Hospital
Dallas, Texas 75230
Contact:
Site Public Contact
972-566-5588

Parkland Memorial Hospital
Dallas, Texas 75235
Contact:
Site Public Contact
214-590-5582
canceranswerline@UTSouthwestern.edu

UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas 75390
Contact:
Site Public Contact
214-648-7097
canceranswerline@UTSouthwestern.edu

El Paso Children's Hospital
El Paso, Texas 79905
Contact:
Site Public Contact
915-298-5444
ranjan.bista@ttuhsc.edu

Cook Children's Medical Center
Fort Worth, Texas 76104
Contact:
Site Public Contact
682-885-2103
CookChildrensResearch@cookchildrens.org

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas 77030
Contact:
Site Public Contact
713-798-1354
burton@bcm.edu

M D Anderson Cancer Center
Houston, Texas 77030
Contact:
Site Public Contact
877-632-6789
askmdanderson@mdanderson.org

Covenant Children's Hospital
Lubbock, Texas 79410
Contact:
Site Public Contact
806-725-8657
mbisbee@providence.org

UMC Cancer Center / UMC Health System
Lubbock, Texas 79415
Contact:
Site Public Contact
806-775-8590

Children's Hospital of San Antonio
San Antonio, Texas 78207
Contact:
Site Public Contact
210-704-2894
bridget.medina@christushealth.org

Methodist Children's Hospital of South Texas
San Antonio, Texas 78229
Contact:
Site Public Contact
210-575-6240
Vinod.GidvaniDiaz@hcahealthcare.com

University Hospital
San Antonio, Texas 78229
Contact:
Site Public Contact
210-358-4176
evelyn.swenson-britt@uhs-sa.com

University of Texas Health Science Center at San Antonio
San Antonio, Texas 78229
Contact:
Site Public Contact
210-450-3800
phoresearchoffice@uthscsa.edu

Scott and White Memorial Hospital
Temple, Texas 76508
Contact:
Site Public Contact
254-724-5407

Primary Children's Hospital
Salt Lake City, Utah 84113
Contact:
Site Public Contact
801-585-5270

University of Vermont and State Agricultural College
Burlington, Vermont 05405
Contact:
Site Public Contact
802-656-8990
rpo@uvm.edu

University of Virginia Cancer Center
Charlottesville, Virginia 22908
Contact:
Site Public Contact
434-243-6303
uvacancertrials@hscmail.mcc.virginia.edu

Children's Hospital of The King's Daughters
Norfolk, Virginia 23507
Contact:
Site Public Contact
757-668-7243
CCBDCresearch@chkd.org

Naval Medical Center - Portsmouth
Portsmouth, Virginia 23708-2197
Contact:
Site Public Contact
757-953-5939

Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia 23298
Contact:
Site Public Contact
CTOclinops@vcu.edu

Providence Regional Cancer System-Aberdeen
Aberdeen, Washington 98520
Contact:
Site Public Contact
360-412-8958
deidre.dillon@providence.org

PeaceHealth Saint Joseph Medical Center
Bellingham, Washington 98225
Contact:
Site Public Contact
360-788-8223

Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington 98310
Contact:
Site Public Contact
308-398-6518
clinicaltrials@sfmc-gi.org

Providence Regional Cancer System-Centralia
Centralia, Washington 98531
Contact:
Site Public Contact
360-412-8958
deidre.dillon@providence.org

Swedish Cancer Institute-Edmonds
Edmonds, Washington 98026
Contact:
Site Public Contact
206-215-3086
PCRC-NCORP@Swedish.org

Providence Regional Cancer Partnership
Everett, Washington 98201
Contact:
Site Public Contact
425-261-3529
marilyn.birchman@providence.org

Swedish Cancer Institute-Issaquah
Issaquah, Washington 98029
Contact:
Site Public Contact
206-215-3086
PCRC-NCORP@Swedish.org

Kadlec Clinic Hematology and Oncology
Kennewick, Washington 99336
Contact:
Site Public Contact
509-783-4637
research@kadlecmed.org

Providence Regional Cancer System-Lacey
Lacey, Washington 98503
Contact:
Site Public Contact
360-412-8958
deidre.dillon@providence.org

PeaceHealth Saint John Medical Center
Longview, Washington 98632
Contact:
Site Public Contact
360-514-2016
kmakin-bond@peacehealth.org

Seattle Children's Hospital
Seattle, Washington 98105
Contact:
Site Public Contact
866-987-2000

Swedish Medical Center-Ballard Campus
Seattle, Washington 98107
Contact:
Site Public Contact
206-215-3086
PCRC-NCORP@Swedish.org

Swedish Medical Center-Cherry Hill
Seattle, Washington 98122-5711
Contact:
Site Public Contact
206-215-3086
PCRC-NCORP@Swedish.org

Swedish Medical Center-First Hill
Seattle, Washington 98122
Contact:
Site Public Contact
206-215-3086
PCRC-NCORP@Swedish.org

Providence Regional Cancer System-Shelton
Shelton, Washington 98584
Contact:
Site Public Contact
360-412-8958
deidre.dillon@providence.org

Providence Sacred Heart Medical Center and Children's Hospital
Spokane, Washington 99204
Contact:
Site Public Contact
800-228-6618
HopeBeginsHere@providence.org

Mary Bridge Children's Hospital and Health Center
Tacoma, Washington 98405
Contact:
Site Public Contact
253-403-1461
research@multicare.org

Madigan Army Medical Center
Tacoma, Washington 98431
Contact:
Site Public Contact
253-968-6144
melissa.a.forouhar.mil@health.mil

PeaceHealth Southwest Medical Center
Vancouver, Washington 98664
Contact:
Site Public Contact
360-514-3940
kmakin-bond@peacehealth.org

Providence Saint Mary Regional Cancer Center
Walla Walla, Washington 99362
Contact:
Site Public Contact
509-897-5993
Cheryl.Dodd@providence.org

North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
Yakima, Washington 98902
Contact:
Site Public Contact
509-574-3535
Memorial-ClinicalTrials@yvmh.org

Providence Regional Cancer System-Yelm
Yelm, Washington 98597
Contact:
Site Public Contact
360-412-8958
deidre.dillon@providence.org

West Virginia University Charleston Division
Charleston, West Virginia 25304
Contact:
Site Public Contact
304-388-9944

West Virginia University Healthcare
Morgantown, West Virginia 26506
Contact:
Site Public Contact
304-293-7374
cancertrialsinfo@hsc.wvu.edu

Green Bay Oncology at Saint Vincent Hospital
Green Bay, Wisconsin 54301-3526
Contact:
John R. Hill
920-433-8889
Christy.Gilchrist@hshs.org

Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin 54301
Contact:
Site Public Contact
920-433-8889
ewd_research_admin@hshs.org

Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin 54303
Contact:
Site Public Contact
920-433-8889
ewd_research_admin@hshs.org

UW Cancer Center Johnson Creek
Johnson Creek, Wisconsin 53038
Contact:
Site Public Contact
920-699-3500
lynda.persico@uwmf.wisc.edu

University of Wisconsin Carbone Cancer Center
Madison, Wisconsin 53792
Contact:
Site Public Contact
800-622-8922

Marshfield Medical Center-Marshfield
Marshfield, Wisconsin 54449
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Children's Hospital of Wisconsin
Milwaukee, Wisconsin 53226
Contact:
Site Public Contact
414-955-4727
MACCCTO@mcw.edu

Saint Vincent Hospital Cancer Center at Oconto Falls
Oconto Falls, Wisconsin 54154
Contact:
Site Public Contact
920-433-8889
ewd_research_admin@hshs.org

HSHS Saint Nicholas Hospital
Sheboygan, Wisconsin 53081
Contact:
Site Public Contact
920-433-8889
ewd_research_admin@hshs.org

Saint Vincent Hospital Cancer Center at Sturgeon Bay
Sturgeon Bay, Wisconsin 54235-1495
Contact:
Site Public Contact
920-433-8889
ewd_research_admin@hshs.org

More Details

NCT ID
NCT03067181
Status
Recruiting
Sponsor
Children's Oncology Group

Detailed Description

PRIMARY OBJECTIVES: I. To evaluate whether a strategy of complete surgical resection followed by surveillance can maintain an overall survival rate of at least 95.7% at two years for pediatric, adolescent and adult patients with stage I (low risk) malignant germ cell tumors, and at least 95% for patients with ovarian pure immature teratoma. II. To compare the event-free survival of a carboplatin versus (vs.) cisplatin-based regimen in the treatment of pediatric, adolescent and young adult patients with standard risk non-seminomatous germ cell tumors. IIa. To compare the event free survival (EFS) of a carboplatin-based regimen (carboplatin [C] etoposide [E] bleomycin [b]) vs. a cisplatin-based regimen (cisplatin [P]Eb) in children (less than 11 years in age) with standard risk germ cell tumors (GCT). IIb. To compare the EFS of a carboplatin-based regimen (BEC) vs. a cisplatin-based regimen (BEP) in adolescents and young adults (ages 11 - < 25 years) with standard risk GCT. SECONDARY OBJECTIVES: I. To compare the incidence of ototoxicity in children, adolescents and young adults with standard risk germ cell tumors treated with carboplatin-based chemotherapy as compared to cisplatin-based chemotherapy. II. To refine and validate a novel patient-reported measure of hearing outcomes for children, adolescents and young adults with standard risk germ cell tumors. EXPLORATORY OBJECTIVES: I. To prospectively determine the correlation of tumor marker decline (alpha-fetoprotein [FP] and beta-human chorionic gonadotropin [HCG]) with clinical outcome in low and standard risk germ cell tumor patients. II. To compare self-reported peripheral neuropathy and other patient-reported outcomes between children, adolescents and young adults with standard risk germ cell tumors treated with carboplatin-based chemotherapy as compared to cisplatin-based chemotherapy. III. Assess the relationship between hearing loss as measured by audiometry with the effects of tinnitus as assessed on the Adolescent and Young Adult Hearing Screening (AYA-HEARS) instrument. IV. To evaluate the prognostic significance of serum micro ribonucleic acid (miRNA)s in stage I testicular cancer (seminoma and non-seminoma) patients by collecting clinical data and serum specimens for future analysis. OUTLINE: Patients with low-risk stage I grade 2, 3 ovarian immature teratoma or stage I non-seminoma malignant germ cell tumors (MGCT)s undergo observation and can transfer to standard risk arm at time of recurrence if eligibility criteria are met. Patients with stage I seminoma testicular MGCT undergo observation, and those with residual/recurrent disease are treated at the discretion of their physician. Patients undergo computed tomography (CT), magnetic resonance imaging (MRI), and/or chest x-ray as well as blood sample collection throughout the trial to monitor for response and recurrence. Patients may also undergo a tumor biopsy throughout the trial. Patients with standard risk 1 are randomized into 1 of 2 arms. ARM I (CEb): Patients receive bleomycin intravenously (IV) over 10 minutes and carboplatin IV over 1 hour on day 1. Patients also receive etoposide IV over 1-2 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study. ARM II (PEb): Patients receive bleomycin IV over 10 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study. Patients with standard risk 2 are randomized into 1 of 2 arms. ARM III (BEC): Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study. ARM IV (BEP): Patients receive bleomycin IV over 10 minutes on days 1, 8, 15, etoposide IV over 1-2 hours on days 1-5, and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study. After completion of study treatment, patients are followed up every 2 months for 12 months, every 3-6 months to 24 months, every 6 months for years 3-5, and then annually for up to 10 years.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.